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ABSTRACT 
Opioids are widely prescribed analgesics, however their use is limited due to 
development of tolerance and addiction, as well as high variability in individual 
response. The development of improved opioid analgesics requires high-throughput 
functional assays to assess large numbers of potential opioid ligands. In this study, 
we assessed the ability of a proprietary “no wash” fluorescent membrane potential 
dye to act as a reporter of µ-opioid receptor (MOR) activation and desensitization via 
activation of G protein-coupled inwardly rectifying potassium channels. AtT-20 cells 
stably expressing mouse MOR were assayed in 96-well plates using the Molecular 
Devices FLIPR membrane potential dye. Dye emission intensity decreases upon 
membrane hyperpolarization. Fluorescence decreased in a concentration-dependent 
manner upon application of range of opioid ligands to the cells, with high efficacy 
agonists producing a decrease of 35% to 40% in total fluorescence. The maximum 
effect of morphine faded in the continued presence of agonist, reflecting receptor 
desensitization. The effects of opioids were prevented by prior treatment with 
pertussis toxin and blocked by naloxone. We have demonstrated this assay to be an 
effective method for assessing ligand signalling at MOR which may potentially be 
scaled up as an additional HTS technique for characterizing novel opioid ligands. 
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INTRODUCTION 
Opioid analgesics are the most widely prescribed drugs in the treatment of moderate 
to severe pain. Despite their powerful analgesic effects, the use of opioids in the 
treatment of chronic pain can be problematic due to the development of tolerance 
and physical or psychological dependence1. Over time, increasing doses of opioids 
become necessary to maintain analgesia. The increased toxic side effects such as 
respiratory depression, constipation and nausea associated with escalating doses of 
opioids can reach unacceptable levels, leading to inadequate pain relief or overdose. 
Opioids, however, continue to be the mainstay of chronic pain treatment due to a 
lack of suitable alternative drugs. As such, there is a substantial need for the 
development of new opioid analgesics, with reduced adverse effects and a 
decreased ability to produce tolerance. The µ opioid receptor (MOR) is the primary 
site of action for most clinically important opioid drugs, and as such is the major 
target for the development of improved opioid analgesic drugs2.  It is generally 
accepted that there are not functionally important subtypes of MOR3, and so aside 
from novel formulations or delivery strategies, the development of new 
pharmacotherapies targeting MOR is likely to focus on subtleties of receptor 
signalling and regulation. 
MOR is a member of the G protein-coupled receptor (GPCR) superfamily, ubiquitous 
cell-surface receptors that act as cellular switches to regulate most cellular signalling 
processes4. GPCR agonists stabilise active conformations of their receptors, leading 
to signalling via both the α and βγ subunits of the associated heterotrimeric G protein 
complex and sometimes also via non-G protein-dependent pathways5.  GPCR 
signalling is complex, with different ligands preferentially activating (or inhibiting) 
distinct signalling pathways at the same receptor5.  There is also increasing evidence 
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that distinct ligands also differentially engage pathways which regulate receptor 
activity during prolonged agonist exposure, a topic of intense investigation with 
regard to opioid receptors6,7,8. These ideas have lead to renewed interest in the 
possibility of developing ligands targeting MOR which engage only subsets of 
signalling systems or regulatory pathways, potentially leading to drugs with more 
favourable clinical profiles.
Drug development typically involves the screening of large libraries of lead 
compounds to identify those capable of binding to and signalling via a receptor. The 
vast array of lead compounds available requires high-throughput screening methods 
for efficient detection of potential therapeutic compounds.  Radioligand binding 
studies are often used to identify candidates, but determination of ligand efficacy 
requires some sort of signalling response.  For opioid receptors, this can be 
achieved using cell lines expressing engineered G proteins which couple to 
processes such as intracellular calcium ([Ca]i) mobilization
9, cAMP-dependent gene
transcription or more traditional assays of adenylyl cyclase (AC) activity which 
require harvesting or lysing of cells10.  In this study we sought to develop a minimally 
invasive assay that reflected a naturalistic coupling of MOR and which could 
potentially be used to readily examine agonist regulation of receptor signalling.  In 
mouse pituitary AtT-20 cells, heterologously expressed MOR inhibit native calcium 
channels (ICa)
11 and activate endogenous G protein gated inwardly rectifying
potassium channels12 (GIRKs), and in both cases this signalling is subject to rapid, 
agonist-induced regulation.  We assessed the suitability of a proprietary fluorescent 
membrane potential assay to act as a robust reporter of MOR activation and 
desensitization in AtT-20 cells, with the view to potentially providing an assay for 
high throughput screening of both these important aspects of MOR function. 
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MATERIALS AND METHODS 
FLAG-MOR Transfection and Cell Culture 
Mouse AtT-20 neuroblastoma cells were stably transfected with the cDNA encoding 
the FLAG epitope-tagged mouse µ-opioid receptor using the transfectant 
Lipofectamine (Gibco BRL) as previously described11. The pcDNA3 FLAG-MOR 
construct was a kind gift from Dr. Lakshmi Devi (Mt Sinai School of Medicine, New 
York, USA). Geneticin (500 µg/ml) was added to select for clones expressing FLAG-
MOR protein. During in situ identification of positive clones using Alexa-488 coupled 
FLAG-MOR antibody (Sigma, F7425), 48 potentially suitable single cells were 
transferred to single wells using a micropipette and were grown to confluence for 
subsequent determination of cell surface MOR binding density.  MOR binding 
density was determined on intact cells by incubation with increasing triplicate 
concentrations of [3H] DAMGO (0.125 - 32 nM; Perkin Elmer, USA) at 4oC in 50mM 
Tris-Cl, pH7.4 for 2h. Briefly, approximately 1 x 105 cells were plated in 24-well plate 
coated with poly-L-lysine overnight. Cells were then rinsed gently twice with 50mM 
Tris-Cl, pH7.4, placed on ice and incubations in the radioligand were commenced. 
Non-specific binding (less than 2% of total binding at  [3H] DAMGO 5 nM) was 
determined in the presence of unlabelled DAMGO (10 µM). At the end of the 
incubation plated cells were rinsed three times with 1 ml 50mM Tris-Cl, pH 7.4 at 
4oC. Cells in each well were then digested for 1 h at room temperature with 100 µl of 
1N NaOH. 100 µl 1N HCl was then added to each well and collected into scintillation 
vials  and bound ligand determined using a liquid scintillation counter (Packard 
Tricarb, USA). Specific binding was plotted, and Kd and Bmax for each clone 
determined using GraphPad Prism. One clone expressing a moderate density of 
surface FLAG-MOR was selected for subsequent experiments.  The Kd for [3H]-
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DAMGO binding was 1.2 nM and receptor density was 10.2 pmol/mg protein. After 
counting cell numbers used for protein determination it was estimated that 2.5 x 107 
cells yielded one mg protein.  Therefore 10.2 pmol/mg protein represents 
approximately 2.5 x 105 receptors per cell. The selected clone of AtT-20 cells stably 
expressing mouse FLAG-MOR  was then cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum (FBS), 100U 
penicillin/streptomycin and 300µg/mL G418. Cells were passaged at 80% 
confluency as required. Assays were carried out on cells up to 25 passages.  Cells 
for assays were grown in 75 cm2 flasks and used at 90% confluence.  The day 
before the assay cells were detached from the flask with trypsin/EDTA (Sigma) and 
resuspended in 10 ml of Leibovitz’s L-15 media supplemented with 1% FBS, 100U 
penicillin/streptomycin and 15 mM glucose.  The cells were plated in volume of 90 µl 
in black walled, clear bottomed 96-well microplates (Corning) and incubated 
overnight in ambient CO2. 
Membrane Potential Assay 
Membrane potential was measured using a FLIPR Membrane Potential Assay kit 
(blue) from Molecular Devices.  The dye was reconstituted with assay buffer supplied 
with the kit or with a low-K modification. The standard assay buffer contained (mM), 
NaCl 145, HEPES 22, Na2HPO4 0.338, NaHCO3 4.17, KCl 5.33, KH2PO4 0.441, 
MgSO4 0.407, MgCl2 0.493, CaCl2 1.26, Glucose 5.56 (pH 7.4, osmolarity 315 ± 5). 
The modified buffer was formulated without the addition of 5.33 mM KCl.  Taking into 
account the K concentration of L-15, the final in-well concentrations of K were 5.55 
mM (standard) and 2.88 mM (low K) respectively.  Prior to the assay, cells were 
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loaded with 90 µl/well of the dye solution without removal of the L-15, giving an initial 
assay volume of 180 µl/well. Plates were then incubated at 37°C at ambient CO2 for 
45 minutes. Fluorescence was measured using a FlexStation 3 (Molecular Devices) 
microplate reader with cells excited at a wavelength of 530 nm and emission 
measured at 565 nm.  Baseline readings were taken every 2 seconds for at least 2 
minutes, at which time either drug or vehicle was added in a volume of 20 µl. 
Further additions were made in volumes of 20 µl, as indicated.  The background 
fluorescence of cells without dye or dye without cells was negligible.  Changes in 
fluorescence were expressed as a percentage of baseline fluorescence after 
subtraction of the changes produced by vehicle addition, which was less than 2 % for 
drugs dissolved in assay buffer or DMSO.  The final concentration of DMSO was not 
more than 0.1%. 
Data Analysis and Calculation of Z' values 
Concentration response data was analysed using PRISM (GraphPad Software Inc., 
San Diego, CA), using four-parameter non-linear regression to fit concentration-
response curves.  The time course of morphine-induced receptor desensitization 
was fit with a single phase exponential to obtain an estimated t/2 for the process.  To 
calculate Z', a measure of the robustness of the assay and its suitability for HTS, the 
membrane potential assay was performed on 3 separate occasions using assay 
buffer as the negative control and 300 nM DAMGO as the positive control in 96-well 
plates.  The Z' factor was calculated as outlined in Zhang et al., (1999)13.  
RESULTS 
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In AtT-20 cells loaded with the proprietary membrane potential dye, addition of the 
peptidergic MOR agonist DAMGO or the prototypic alkaloid opioid morphine 
produced a rapid decrease in fluorescence, consistent with hyperpolarization of the 
cells (Figure 1).  It took about 30s for high concentrations of morphine to maximally 
hyperpolarise the cells (Table 1).  The decrease in fluorescence produced by 
morphine was concentration dependent and reversed by addition of the opioid 
receptor antagonist naloxone (Figure 2A).  Addition of increasing concentrations of 
naloxone produced a parallel shift in the concentration response curve for morphine, 
with a pA2 of -8.5 ± 0.1, (2.9 ± 0.5 nM, n=3), a value consistent with the reported 
binding affinity of naloxone at mouse MOR (2 nM)14 (Figure 2B). Pretreatment of 
cells overnight with pertussis toxin (200 ng/ml) prevented the decrease in 
fluorescence by DAMGO and morphine (Figure 3).  Addition of morphine or DAMGO 
to AtT-20 cells not transfected with MOR produced no change in fluorescence. 
Using the assay buffer supplied with the kit, the maximal decrease in fluorescence 
produced by DAMGO was 31 ± 1% (n=6).  We sought to optimise the assay by 
decreasing extracellular [K]Ex from 5.6 mM to 2.9 mM in order to make the reversal 
potential (Ke) for K more negative.  The reduction in [K]Ex was achieved by dissolving 
the dye in saline containing no added KCl.  The reduction of [K]Ex resulted in 
maximally effective concentrations of DAMGO producing a 7 % greater decrease in 
total fluorescence (P < 0.01, Students T-test).  The Emax and pEC50 for DAMGO in 
5.6 mM [K]Ex were 31 ± 1% and 8.3 ± 0.1 respectively, while in 2.9 mM [K]Ex, Emax 
and pEC50 for DAMGO were 38 ± 2% and 8.3 ± 0.1 respectively (Figure 4). 
The maximum response elicited by DAMGO was similar to that elicited by 
somatostatin (Emax = 39 ± 3.2%, pEC50 8.7), which acts at endogenous sst2 and sst5
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receptors to activate GIRK channels in AtT-20 cells15.  We independently assessed 
the changes in fluorescence produced by altering the membrane K+ permeability by 
incubating AtT-20 cells with nigericin, a potassium selective antibiotic ionophore16.  A 
maximally effective concentration of nigericin (1 µM) produced a decrease in 
fluorescence signal of 50 ± 3%, which was not decreased any further upon the 
addition of 300 nM DAMGO. The fluorescent signal observed after nigericin 
incubation may reflect the signal when the membrane potential of the cells is driven 
to EK
16 (Figure 5).
We assessed the capacity of the fluorescence assay to reliably detect opioid ligands 
of differing efficacy by treating AtT-20MOR cells with a range of structurally distinct 
opioid ligands.  All agonists tested produced a concentration-dependent decrease in 
cellular fluorescence.  High efficacy agonists such as fentanyl, DAMGO and β-
endorphin produced a maximum decrease in fluorescence of 35-40%, while 
morphine, buprenorphine and pentazocine were shown to be partial agonists (Figure 
6).  A rank order of ligand efficacy was established (Table 1). 
We assessed the suitability of this assay for HTS by calculating the Z’ factor, a 
measure of the assay robustness. An assay with a Z’ factor of between 0.5 - 1 is an 
excellent assay in terms of signal/noise ratio and data reproducibility13. The Z’ factor 
for this assay was calculated in multiple experiments, with Z’ values of 0.6, 0.7 and 
0.7, indicating that the assay is suitable for HTS. 
A hallmark of opioid signalling is agonist-dependent desensitization, where 
continuous application of agonist results in a relatively rapid decline in receptor 
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activation. The decrease in fluorescence produced by application of high 
concentrations of morphine faded in the continued presence of agonist, reaching a 
plateau after about 30 minutes (Figure 7A).  In order to assess whether the decline in 
fluorescence reflected a change in MOR signalling, we incubated cells with a high 
concentration of morphine (1 µM) and then challenged them with subsequent 
addition of 10 µM morphine.  The response to 10 µM morphine declined significantly 
over time.  When fit with a one phase exponential association function, the peak 
response to 10 µM morphine declined with a τ of 490 s (95 % C.I. 413–603 s) to a 
maximum inhibition of 72 % (95 % C.I. 67–76 %, , Figure 7B).  In order to assess 
whether the decline in morphine effectiveness reflected heterologous 
desensitization, we repeated the experiments using 1 µM somatostatin as the 
challenge drug.  The response to somatostatin also declined during continuous 
morphine exposure (τ of 460 s, 95 % C.I. 331-748 s), the maximum inhibition of the 
somatostatin response was 30 % (95 % C.I. 27-34 %).  Preincubation with naloxone 
(1 µM) did not affect the hyperpolarization produced by somatostatin (10 nM; control 
36 ± 1 %, in naloxone 35 ± 1 %). 
DISCUSSION 
In this study, we have developed a real time, no wash, fluorescence based assay for 
MOR-mediated hyperpolarisation of intact AtT-20 cells.  We used a proprietary 
membrane potential sensitive dye from Molecular Devices to measure membrane 
hyperpolarisation following MOR mediated GIRK channel activation12. The 
fluorescent signal rapidly and reliably decreased after opioid application, and this 
decrease in signal could be completely reversed by the opioid naloxone applied for 
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up to at least 2 hours after agonist, indicating the stability of the dye signal and 
capacity of the systems to report continued activation of the µ-receptors for 
prolonged periods, albeit in the face of receptor desensitization.  The ability to 
continuously measure the consequences of opioid receptor activation in cells for 
such prolonged periods of time has only previously been possible using high 
resistance electrode recordings from single neurons in brain slices7,17.  Activation of 
endogenous sst receptors in AtT-20 cells15 produced a reduction in fluorescence 
similar that seen following MOR activation, and in both cases this reduction was less 
than that produced by application of the K-selective ionophore nigericin16.  
The potency and efficacy of the opioid agonists correlate well with previous studies 
in AtT-20 cells, and with studies in native neurons where activation of GIRK channels 
or inhibition of ICa was used to determine agonist intrinsic activity
11,18,19,20.  The data
we obtained with the hyperpolarization assay is similar to that we obtained when we 
measured MOR inhibition of calcium currents in these cells – the rank order of 
potency in both studies is DAMGO > methadone = morphine > pentazocine11, and in 
both studies morphine and pentazocine have reduced efficacy when compared with 
DAMGO.  The only notable inconsistencies are the apparently greater efficacy of 
endomorphin 1 and 2 compared with methadone in the present study.  Many studies 
have reported the endomorphins as being partial agonists18,21, while methadone has 
been reported to be an agonist with a similar efficacy to DAMGO11,22,23.  The most 
likely explanation for the discrepancy in our study is that methadone appeared to 
have a reduced maximal effect because of its propensity to block K channels, 
including the GIRK channels likely to contribute to the hyperpolarisation measured in 
the present study22,24.  Conversely, the observation that the maximum effect of the 
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endomorphins was similar to that of well recognized high efficacy agonists suggests 
the presence of some spare receptors in our system, as noted previously with similar 
cell lines11.  It is also possible that the efficacy discrepancies reflect subtle bias in 
ligand signalling to one pathway over another in different tissues, and it is worth 
noting that endomorphins have recently been reported to show such bias in assays 
of β-arrestin recruitment25,26. 
Continuous application of opioid agonists usually results in desensitization of 
receptor signalling, a complex process that may involve receptor phosphorylation 
and sequestration.  The apparent stability of the membrane potential assay led us to 
explore whether it could be used to investigate µ-opioid receptor desensitization. 
The hyperpolarisation produced by high concentrations of morphine or DAMGO 
appeared to wane over time, and when the cells were challenged with a 
concentration of agonist that should saturate the cell surface receptors there was a 
marked decrease in this response after only a few minutes exposure to agonist, 
consistent with analogous studies performed in locus coeruleus neurons27 or cell 
lines transfected with µ-opioid receptors and GIRK channels28.  We were able to 
make use of the endogenous sst receptors in the AtT-20 cells to determine whether 
exposure to desensitizing concentrations of opioid agonist affected signalling through 
other receptors.  The time constant for the desensitization of signalling produced by 
morphine was slower than that reported in our previous study of opioid signalling 
which utilized inhibition of ICa in AtT-20 cells, this may reflect a distinct recruitment of 
desensitization processes by morphine in intact cells compared with cells dialyzed by 
patch-clamp recording11. A major limitation of using the Flexstation for 
desensitization assays is the inability to wash off drugs, which makes it impossible to 
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do experiments where receptor function is repeatedly probed with concentrations of 
drugs that activate only a portion of receptors11,27.  Nevertheless, the potential of this 
assay to quickly test multiple agonists or putative modulators of receptor 
desensitization in an intact system makes it an attractive option. 
GIRK channel activation has most commonly been assessed using 
electrophysiological techniques, but assays potentially suitable for high throughput 
screening have been reported utilizing thallium flux29 or commercially available 
membrane potential dyes30,31.  Thallium is toxic and apparently unsuitable for all cell 
lines31 while other membrane potential sensitive dyes (Di-Bac, HLB 021-152) give 
results qualitatively similar to those reported here30,31.  The EC50 value for the
somatostatin-induced hyperpolarisation of our AtT-20 cells was 2 nM, very similar to 
that previously reported using another dye (4 nM)31.  However, it should be noted 
that under our standard conditions the proprietary dye gives a change in 
fluorescence of approximately 40% following GPCR activation, which compares with 
changes of approximately 10% using DiBAC4 in HL-1 or HLB 021-152 in AtT-20 
cells30,31.  Removal of media and/or washing or the cells is also required during dye 
loading of commercial dyes used previously, this increases assay time and may 
promote cell detachment from the microplate wells31,32. 
This assay has a number of advantages as a rapid screen for assessing ligand 
potency and efficacy at µ-opioid receptors.  It is rapid, real-time, only requires the 
addition of a single reagent and is it performed in intact cells.  When compared with 
assays of Gα subunit activation – either [35S]GTPγS binding assays or assays which 
directly measure agonist-stimulated GTPase activity33, the GIRK assay is far simpler, 
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14 
requires no handling of radioactivity and provides a real time measure of receptor 
activation rather than a single point determination.  However, the Gα subunit 
activation assays will provide a more sensitive discriminator of efficacy in cells with a 
low to moderate expression of receptors because the assay is constrained only by 
the amount of accessible Gα subunit in the cells, and this is usually not limiting33. By 
contrast, assays of AC regulation via measurement of cAMP accumulation have 
been adapted for use in whole cells, however these assays usually require 
incubation steps and either cell lysis followed by addition of several reagents or the 
use of cells transfected with enzymes which catalyse the production of a fluorescent 
substrate or with fluorescently labelled reporter proteins10.  Assays of AC activity can 
be very sensitive and also detect cAMP levels over a large range of concentrations 
but in general when assaying the activity of Gi/Go-coupled receptors such as the µ-
opioid receptor it is usually necessary to artificially elevate cAMP levels with forskolin 
in order to obtain an appropriate signal window for determining AC inhibition by the 
Gi/Go-derived Gα subunits.  Nevertheless, assays of AC inhibition represent the most 
flexible and straightforward way of studying Gα (as opposed to Gβγ) signalling in a 
high throughput environment. 
While both GTPγS binding and cAMP accumulation assays have been widely used 
for studying desensitization of opioid receptor signalling, the usual requirement for 
control cells to be incubated with agonist for at least 10-15 minutes makes 
interpretation of the data problematic, as receptor desensitization will be occurring 
during this time (e.g. Figure 7)7.   
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Other relatively straightforward strategies for real-time measurement of MOR-
mediated signalling involve measuring [Ca]i concentration using Ca
2+ sensitive
fluorescent dyes.  This approach provides relatively rapid real time response, and 
assays of [Ca]i concentration can be amenable to studying receptor 
desensitization34,35.  Interestingly, we were unable to activate intracellular Ca release 
in AtT-20 cells via MOR or any of the Gαq receptors reportedly expressed in this cell 
line36 (data not shown).  
This assay offers an alternative approach for measuring MOR activation and 
desensitisation by targeting a naturalistic Gβγ-mediated signalling pathway. Our 
results show the membrane potential assay to be a rapid, reliable and inexpensive 
method for identifying ligands that modulate GIRK activity, and may be scaled up to 
enable high-throughput screening for novel opioid drugs. 
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Table 1: Potencies and efficacies of the range of structurally distinct opioid ligands 
tested using the membrane potential assay in AtT-20 cells. Ligands are ranked in 
order of efficacy. Ligands with Emax significantly different to that of DAMGO are 
marked with * (P < 0.05, extra sum of squares F test).  Latency is the time taken for 
the peak signal to be reached after a maximal concentration of drug was added. 
OPIOID AGONIST pEC50 Emax (%) Hill Slope Latency (s) 
DAMGO 8.3 ± 0.1 38 ± 2 0.8 ± 0.1 29 ± 1 
Endomorphin 2 8.4 ± 0.1 37 ± 2 1.0 ± 0.1 32 ± 2 
Endomor phin 1 8.7 ± 0.1 36 ± 1 0.9 ± 0.1 27 ± 1 
B-endorphin 7.0 ± 0.1 36 ± 3 1.2 ± 0.2 33 ± 4 
Fentanyl 9.3 ± 0.1 35 ± 1 1.0 ± 0.1 27 ± 2 
Met-Enkephalin * 8.5 ± 0.1 34 ± 1 0.8 ± 0.1 30 ± 3 
Methadone * 7.6 ± 0.1 32 ± 1 1.2 ± 0.2 29 ± 3 
Morphine * 7.7 ± 0.1 31 ± 1 1.0 ± 0.2 29 ± 2 
Oxycodone * 6.7 ± 0.1 28 ± 1 1.2 ± 0.1 24 ± 3 
Buprenorphine * 8.0 ± 0.1 21 ± 1 0.8 ± 0.3 12 ± 4 
Pentazocine * 6.2 ± 0.2 5 ± 1 1.6 ± 0.3 18 ± 2 
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Figure 1: Example traces of fluorescent signal in the membrane potential assay over 
300 sec. Baseline readings were taken every 2 sec for 120 sec, at which point 
increasing concentrations of DAMGO (3 nM, 30 nM, 300 nM) were added to AtT-
20MOR cells, resulting in concentration-dependent decreases in fluorescent signal 
as shown. 
Figure 2: (A) Trace of fluorescent signal illustrating the reversal of DAMGO 
stimulated decrease in signal by MOR antagonist naloxone. 1 µM DAMGO/HBSS 
was added to AtT-20MOR cells at 120 secs, followed by addition of 1 µM naloxone 
at 240 secs. The DAMGO stimulated decrease in fluorescent signal was completely 
reversed by naloxone. Naloxone had no effect when applied without previous 
addition of DAMGO. (B) Concentration response curve for morphine, both alone and 
with the addition of 3 nM, 10 nM and 100 nM naloxone. The addition of naloxone 
produced a parallel shift in the morphine concentration response curve with a pA2 of 
-8.5 ± 0.1, (2.9 ± 0.5 nM, n=3). 
Figure 3: The decrease in fluorescent signal observed with 30 nM DAMGO or 100 
nM morphine was abolished following overnight incubation of AtT-20-MOR cells with 
200ng/mL PTX. 
Figure 4: Decreasing extracellular potassium concentration ([K]Ex) increases the 
maximum change in fluorescent signal observed with DAMGO. Concentration-
response curves were generated for DAMGO activation of GIRK channels in both 
low [K]Ex (2.9 mM) and high [K]Ex (5.5 mM) conditions. Emax in low [K]Ex was 38 ± 2%, 
21% higher than in high [K]Ex (Emax 31± 1%; P < 0.01). 
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Figure 5: Treatment of AtT-20-MOR cells with nigericin, a K selective antibiotic 
ionophore, caused a greater decrease in fluorescent signal than the maximally 
effective concentration of DAMGO (P < 0.05). 1 µM nigericin (heavy trace), or 
vehicle (light trace) was added to cells at 120 secs. Nigericin caused a decrease of 
50 ± 3% in fluorescent signal. Membrane potential was allowed to reach equilibrium 
before the addition of 300 nM DAMGO at 1500 sec, which did not cause any further 
decrease in signal. 
Figure 6: Concentration response curves for DAMGO, morphine, buprenorphine and 
pentazocine activation of GIRK channels, illustrating the differences in agonist 
potency and efficacy. Morphine, buprenorphine and pentazocine all showed partial 
agonist activity with Emax values of 31 ± 1%, 21 ± 1% and 5 ± 1% respectively. 
Figure 7: Desensitization of MOR signalling in AtT-20 cells. Continuous application 
of morphine (1 µM) reduces the response to a subsequent addition of a high 
concentration of morphine or SRIF. Panel A shows example traces from an 
experiment where a high concentration of morphine (10 µM) or SRIF (1 µM) was 
added 30 minutes after the desensitizing concentration of 1 µM morphine (heavy 
trace) or 30 minutes after the addition of vehicle (light trace). Panel B shows the time 
course of the decline in response to 10 µM morphine or 1 µM SRIF in the continued 
presence of 1 µM morphine.  Data are expressed as a percentage of the control 
response to drug added at the same time after the run commenced, and represent 
the mean ± s.e.m. of 3 - 8 determinations, each in duplicate or triplicate.  The data 
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was fit with an single exponential function to derive a t/2 for desensitization (490s for 
morphine/morphine, 460s for morphine/somatostatin). 
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